# Ketoconazole With or Without Alendronate Sodium in Treating Patients With Metastatic Prostate Cancer

> **NCT00019695** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)**

## Conditions studied

- Stage IV Prostate Cancer
- Bone Metastases
- Adenocarcinoma of the Prostate
- Recurrent Prostate Cancer

## Interventions

- **DRUG:** alendronate sodium
- **DRUG:** ketoconazole

## Key facts

- **NCT ID:** NCT00019695
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 1999-03
- **Primary completion:** —
- **Final completion:** 2005-03
- **Target enrollment:** — (—)
- **Last updated:** 2024-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00019695

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00019695, "Ketoconazole With or Without Alendronate Sodium in Treating Patients With Metastatic Prostate Cancer". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00019695. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*